Systematic literature review of traits and outcomes reported in randomised controlled trials of asthma with regular dosing of inhaled corticosteroids with short-acting β2-agonist reliever, as-needed ICS/formoterol, or ICS/ formoterol maintenance and reliever therapy

被引:1
|
作者
Roche, Nicolas [1 ]
Yorgancioglu, Arzu [2 ]
Cruz, Alvaro A. [3 ]
Garcia, Gabriel [4 ]
Lavoie, Kim L. [5 ,6 ]
Abhijith, Pg [7 ,11 ]
Verma, Manish [8 ]
Majumdar, Anurita [9 ]
Chatterjee, Swarnendu [10 ]
机构
[1] Univ Paris Cite, Hop Cochin, AP HP Ctr, Pneumol, Paris, France
[2] Celal Bayar Univ, Dept Pulmonol, Manisa, Turkiye
[3] ProAR & Univ Fed Bahia, Salvador, Brazil
[4] CEPIR, Resp Res Ctr, La Plata, Argentina
[5] Univ Quebec Montreal UQAM, Montreal, PQ, Canada
[6] Hop Sacre Coeur Montreal, CIUSSS NIM, Montreal Behav Med Ctr, Montreal, PQ, Canada
[7] Global Med Affairs, Gen Med, GSK, Amsterdam, Netherlands
[8] Global Med Affairs, GSK, Gen Med, Mumbai, India
[9] Global Med Affairs, GSK, Gen Med, Singapore, Singapore
[10] GSK, Hyderabad, Telangana, India
[11] Inogen, Amsterdam, Netherlands
关键词
Maintenance therapy; Reliever therapy; Respiratory clinical trials; Treatable traits; DAILY FLUTICASONE FUROATE; TO-MODERATE ASTHMA; BUDESONIDE/FORMOTEROL MAINTENANCE; SINGLE INHALER; DOUBLE-BLIND; BUDESONIDE-FORMOTEROL; SALMETEROL/FLUTICASONE PROPIONATE; SEVERE EXACERBATIONS; SUBGROUP ANALYSIS; PARALLEL-GROUP;
D O I
10.1016/j.rmed.2023.107478
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Asthma treatments based solely on diagnostic label do not benefit patients equally. To identify patient traits that may be associated with improved treatment response to regular inhaled corticosteroid (ICSs) dosing with short-acting beta(2)-agonist reliever or ICS/formoterol-containing therapy, a systematic literature review (SLR) was conducted.Methods: Searches of databases including MEDLINE and Embase identified randomised controlled trials (RCTs) of patients with asthma, aged >= 12 years, published 1998-2022, containing >= 1 regular ICS dosing or ICS/formoterol-containing treatment arm, and reporting patient traits and outcomes of interest. Relevant data was extracted and underwent a feasibility assessment to determine suitability for meta-analysis.Results: The SLR identified 39 RCTs of 72,740 patients and 90 treatment arms, reporting 11 traits and 11 outcomes. Five patient traits (age, body mass index, FEV1, smoking history, asthma control) and five outcomes (exacerbation rate, lung function, asthma control, adherence, time to first exacerbation) were deemed feasible for inclusion in meta-analyses due to sufficient comparable reporting. Subgroups of clinical outcomes stratified by levels of patient traits were reported in 16 RCTs.Conclusion: A systematic review of studies of regular ICS dosing with SABA or ICS/formoterol-containing treatment strategies in asthma identified consistent reporting of five traits and outcomes, allowing exploration of associations with treatment response. Conversely, many other traits and outcomes, although being potentially relevant, were inconsistently reported and limited subgroup reporting meant analyses of treatment response for subgroups of traits was not possible. We recommend more consistent measurement and reporting of clinically relevant patient traits and outcomes in respiratory RCTs.
引用
收藏
页数:7
相关论文
共 11 条
  • [1] ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis
    Hatter, Lee
    Bruce, Pepa
    Braithwaite, Irene
    Holliday, Mark
    Fingleton, James
    Weatherall, Mark
    Beasley, Richard
    ERJ OPEN RESEARCH, 2021, 7 (01)
  • [2] A network meta-analysis of the association between patient traits and response to regular dosing with ICS plus short-acting 82-agonist reliever or ICS/formoterol reliever only in mild asthma
    Yorganciog, Arzu
    Cruz, Alvaro A.
    Garcia, Gabriel
    Lavoie, Kim L.
    Roche, Nicolas
    Verma, Manish
    Majumdar, Anurita
    Chatterjee, Swarnendu
    RESPIRATORY MEDICINE, 2024, 226
  • [3] BUDESONIDE/FORMOTEROL (AS SYMBICORT) FOR MAINTENANCE AND RELIEVER THERAPY COMPARED WITH INHALED CORTICOSTEROIDS PLUS SHORT-ACTING β2 AGONISTS OR ALTERNATIVE INHALED CORTICOSTEROID AND LONG-ACTING β2 AGONIST REGIMENS PLUS SHORT-ACTING β2 AGONIST RELIEVER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
    Edwards, S. J.
    Harrison, T. W.
    Naya, I. P.
    von Maltzahn, R.
    THORAX, 2008, 63 : A122 - A122
  • [4] Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
    Hatter, Lee
    Houghton, Claire
    Bruce, Pepa
    Holliday, Mark
    Eathorne, Allie
    Pavord, Ian
    Reddel, Helen K.
    Hancox, Robert J.
    Braithwaite, Irene
    Oldfield, Karen
    Papi, Alberto
    Weatherall, Mark
    Beasley, Richard
    BMJ OPEN RESPIRATORY RESEARCH, 2022, 9 (01)
  • [5] A network meta-analysis of the association between patient traits and response to regular dosing with ICS/long-acting β2-agonist plus short-acting β2 agonist reliever or maintenance and reliever therapy for asthma
    Yorgancioglu, Arzu
    Cruz, Alvaro A.
    Garcia, Gabriel
    Lavoie, Kim L.
    Roche, Nicolas
    Abhijith, P. G.
    Verma, Manish
    Majumdar, Anurita
    Chatterjee, Swarnendu
    RESPIRATORY MEDICINE, 2023, 218
  • [6] Single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis
    Rodriguez-Martinez, Carlos E.
    Sossa-Briceno, Monica P.
    Castro-Rodriguez, Jose A.
    JOURNAL OF ASTHMA, 2025, 62 (03) : 500 - 507
  • [7] Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study
    Cheng, Shih-Lung
    Ho, Ming-Lin
    Lai, Yun-Fa
    Wang, Hao-Chien
    Hsu, Jeng-Yuan
    Liu, Shih-Feng
    Huang, Ming-Shyang
    Lee, Cheng-Hung
    Lin, Ching-Hsiung
    Hang, Liang-Wen
    Liu, Yu-Chih
    Yang, Kuang-Yao
    Wang, Jia-Horng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5441 - 5450
  • [8] Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study (vol 14, pg 5441, 2020)
    Cheng, Shih-Lung
    Ho, Ming-Lin
    Lai, Yun-Fa
    Wang, Hao-Chien
    Hsu, Jeng-Yuan
    Liu, Shih-Feng
    Huang, Ming-Shyang
    Lee, Cheng-Hung
    Lin, Ching-Hsiung
    Hang, Liang-Wen
    Liu, Yu-Chih
    Yang, Kuang-Yao
    Wang, Jia-Horng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 515 - 516
  • [9] Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting β2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review
    Almutairi, Mohammed
    Marriott, John F.
    Mansur, Adel
    BMJ OPEN, 2023, 13 (08):
  • [10] Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
    Gary T. Ferguson
    Patrick Darken
    Shaila Ballal
    Mohd Kashif Siddiqui
    Barinder Singh
    Sumeet Attri
    Ulf Holmgren
    Enrico de Nigris
    Advances in Therapy, 2020, 37 : 2956 - 2975